The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs) to chronic myeloid leukemia (CML) therapy has revolutionized the treatment of this disease. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.